Current
Research in
Ophthalmology >>

A Multicenter, Randomized, Masked, Controlled Study to Evaluate Retisert™, an Intravitreal Fluocinolone Acetonide Implant, in the Treatment of Patients with Diabetic Macular Edema

Principal Investigator:

Ronald Gentile, M.D.

Enrollment Status:

Completed

Objective:

To evaluate Retisert™ in the management of patients with diabetic macular edema.

CONCLUSION:

The two year trial results demonstrated that 30% of eyes receiving standard of care (repeat laser treatment) had a worsening of their Diabetic Retinopathy compared with only 10% of eyes receiving a RetisertTM implant. This was statistically significant. RetisertTM also reduced retinal thickening involving the fovea (the centre most part of the macula responsible for sharp, central vision) and led to a statistically significant three line improvement in vision.

For more information:

ClinicalTrials.gov

Home > Current Research > Clinical Trials in Ophthalmology > Results > CONTROLLED STUDY TO EVALUATE RETISERT™, AN INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANT, IN THE TREATMENT OF PATIENTS WITH DIABETIC MACULAR EDEMA